• Mashup Score: 28

    A randomized, controlled trial (RCT) shows that even at a higher dose and longer treatment duration, the antimalarial drug ivermectin didn’t shorten the time to a sustained recovery from COVID-19. In the double-blind trial, published yesterday in JAMA, a team led by Duke University researchers evaluated time to sustained recovery among 1,206 COVID-19 patients at 93 US sites from Feb 16 to Jul…

    Tweet Tweets with this article
    • Higher ivermectin dose, longer duration still futile for #COVID19, trial finds The median time to sustained recovery was 11 days in both the #ivermectin and placebo group https://t.co/ip3TRgQWNg https://t.co/eTuuQ74stV

  • Mashup Score: 0
    Wolters Kluwer Health - 1 year(s) ago

    JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…

    Tweet Tweets with this article
    • Our best-read column last year by the late James R. Roberts, MD: #Ivermectin had been touted as a #COVID19 treatment, but the evidence was clear: It just didn’t work. #CME #FOAMed https://t.co/invIF9Ysy3 #bestof2022 https://t.co/gUwJ3h1GIR

  • Mashup Score: 3

    MedinCell is a pharmaceutical company at premarketing stage that develops innovative long-acting injectable medicines in many therapeutic areas.

    Tweet Tweets with this article
    • SAIVE randomised, double-blind, placebo-controlled clinic study brings the total to 16 statistically significant studies showing #Ivermectin is highly effective at protecting people from becoming infected with #Covid. Why is this not being covered? https://t.co/qqg3zr24Z9…